Nivolumab for the treatment of unresectable pleural mesothelioma

References

• Ministry of the Environment Government of Japan. [cited 2019 Aug 15]. Available from: www.env.go.jp/air/asbestos/registration/
   Google Scholar
• Jasani B, Gibbs A. Mesothelioma not associated with asbestos exposure. Arch Pathol Lab Med. 2012;136:262–267.
   PubMed Web of Science ®Google Scholar
• Roe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev. 2015;24:115–131.
   PubMed Web of Science ®Google Scholar
• Carbone M. Simian virus 40 and human tumors: it is time to study mechanisms. J Cell Biochem. 1999;76:189–193.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Carbone M. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer. 2003;5:177–181.
   PubMedGoogle Scholar
• Carbone M, Rizzo P, Pass H. Simian virus 40: the link with human malignant mesothelioma is well established. Anticancer Res. 2000;20:875–877.
   PubMed Web of Science ®Google Scholar
• Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–672.
   PubMed Web of Science ®Google Scholar
• Mutti L, Peikert T, Robinson BWS, et al. Scientific advances and new frontiers in mesothelioma therapeutics. J Thorac Oncol. 2018 Sep;13(9):1269–1283.
   PubMed Web of Science ®Google Scholar
• Carbone M, Adusumilli PS, Alexander HR Jr, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69:402–429. (in press).
   PubMed Web of Science ®Google Scholar
• Forde PM, Scherpereel A, Tsao AS. Use of immune checkpoint inhibitors in mesothelioma. Curr Treat Options Oncol. 2019;20:18.
   PubMed Web of Science ®Google Scholar
• Sweis RF, Luke JJ. Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res. 2017;120:1–9.
   PubMed Web of Science ®Google Scholar
• Ninomiya K, Hotta K. Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opin Biol Ther. 2018 Oct;18(10):1015–1021.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015 Apr 3;348(6230):56–61.
   PubMed Web of Science ®Google Scholar
• Bedke J, Kruck S, Gakis G, et al. Checkpoint modulation–A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother. 2015;11(5):1201–1208.
   PubMed Web of Science ®Google Scholar
• Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458:206–210.
   PubMed Web of Science ®Google Scholar
• Wang C, Thudium KB, Han M, et al. In vitro characterization of the anit-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846–856.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644.
   PubMed Web of Science ®Google Scholar
• Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:3852–3859.
   PubMed Web of Science ®Google Scholar
• Hotta K, Matsuo K, Ueoka H, et al. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol. 2004;15:1782–1789.
   PubMed Web of Science ®Google Scholar
• Hotta K, Matsuo K. Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2007;2:96.
   PubMed Web of Science ®Google Scholar
• Hotta K, Fujiwara Y, Matsuo K, et al. Recent improvement in the survival of patients with advanced non small cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer. 2007;109:939–948.
   PubMed Web of Science ®Google Scholar
• Hotta K, Takigawa N, Hisamoto-Sato A, et al. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama lung cancer study group trial 1002. Jpn J Clin Oncol. 2013;43:1115–1123.
   PubMed Web of Science ®Google Scholar
• Ninomiya K, Hotta K, Hisamoto-Sato A, et al. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama lung cancer study group trial 1201. Int J Clin Oncol. 2016;21:81–87.
   PubMed Web of Science ®Google Scholar
• Hotta K, Ninomiya K, Takigawa N, et al. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. Jpn J Clin Oncol. 2015;45:603–604.
   PubMed Web of Science ®Google Scholar
• Nishii K, Hotta K, Ninomiya K, et al. Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: a sub-analysis of data from the two Okayama lung cancer study group prospective feasibility studies. Respir Investig. 2019;57:460–465. (in press).
   Web of Science ®Google Scholar
• Tsao AS, Lindwasser OW, Adjei AA, et al. Current and future management of malignant mesothelioma: a consensus report from the national cancer institute thoracic malignancy steering committee, international association for the study of lung cancer, and mesothelioma applied research foundation. J Thorac Oncol. 2018 Nov;13(11):1655–1667.
   PubMed Web of Science ®Google Scholar
• Hato SV, Khong A, de Vries IJ, et al. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 2014;20:2831–2837.
   PubMed Web of Science ®Google Scholar
• Nowak A, Kok P, Lesterhuis W, et al. OA08.02 DREAM-a phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: final result. J Thorac Oncol. 2018;13(10suppl):S338–S339.
   Web of Science ®Google Scholar
• Fujimoto N, Aoe K, Kozuki T, et al. A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol. Clin Lung Cancer. 2018 Sep;19(5):e705–e707.
   PubMed Web of Science ®Google Scholar
• Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr;16(4):447–456.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1343–1373.
   PubMed Web of Science ®Google Scholar
• Zauderer MG, Kass SL, Woo K, et al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 2014;84:271–274.
   PubMed Web of Science ®Google Scholar
• Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13:1569–1576.
   PubMed Web of Science ®Google Scholar
• Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT). Clin Cancer Res. 2019;25:5485–5492. (in press).
   Web of Science ®Google Scholar
• Yap TA, Aerts JG, Popat S, et al. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475–488.
   PubMed Web of Science ®Google Scholar
• Scherpereel A, Mazieres J, Greillier L, et al. French cooperative thoracic intergroup. nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019 Feb;20(2):239–253.
   PubMed Web of Science ®Google Scholar
• Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019 Mar;7(3):260–270.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. KEYNOTE-024 investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 9;373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Zauderer MG. Nivo-lution in mesothelioma. Clin Cancer Res. 2019 Sep 15;25(18):5438–5440.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277–1290.
   PubMed Web of Science ®Google Scholar